Table 3.
Standardised scores (%) on the AGREE instrument assigned to included CPGs/consensus
| Guidelines | Domain (%) | AGREE overall assessment | Radar map area (%) | ||||||
| Scope and purpose | Stakeholder involvement | Rigour of development | Clarity and presentation | Applicability | Editorial independence | Score (%) | |||
| Guidelines from Europe | |||||||||
| SIGN | 81.5 | 94.4 | 89.6 | 92.6 | 66.7 | 66.7 | 77.8 | ●●● | 67.5 |
| NICE | 87 | 87 | 87.5 | 85.2 | 73.6 | 63.9 | 88.9 | ●★★ | 65.3 |
| KCE | 87.1 | 87 | 85.4 | 88.9 | 41.7 | 75 | 72.2 | ●●● | 58.3 |
| SIOG | 64.9 | 50 | 56.9 | 87 | 34.7 | 47.2 | 72.2 | ★★★ | 31.3 |
| AGO | 64.8 | 20.4 | 49.3 | 53.7 | 23.6 | 75.1 | 55.6 | ★★▲ | 21.5 |
| EUSOMA | 68.5 | 40.7 | 26.4 | 72.2 | 23.6 | 44.4 | 50.0. | ★★★ | 20.4 |
| ESMO | 62.9 | 31.5 | 43.8 | 79.6 | 12.5 | 58.3 | 55.6 | ★★★ | 19.3 |
| SEOM | 70.4 | 27.8 | 30.6 | 40.7 | 6.9 | 33.3 | 22.2 | ★▲▲ | 7.6 |
| Guidelines from North America | |||||||||
| ASCO | 92.6 | 77.8 | 88.2 | 83.3 | 61.1 | 91.7 | 94.4 | ●●● | 67.7 |
| CCO | 92.6 | 61.1 | 86.9 | 83.3 | 34.7 | 88.9 | 72.2 | ●●★ | 54 |
| NCCN | 61.1 | 75.9 | 79.9 | 81.5 | 51.4 | 66.7 | 72.2 | ●●★ | 48.2 |
| SSO-ASTRO | 90.7 | 31.5 | 76.4 | 87 | 12.5 | 75 | 77.8 | ●★★ | 34.6 |
| ACR | 61.1 | 31.4 | 65.9 | 51.9 | 15.3 | 50 | 55.6 | ★★★ | 20 |
| SASK | 57.4 | 13 | 14.6 | 68.5 | 13.9 | 8.3 | 44.4 | ▲▲▲ | 5.8 |
| Guidelines from Asian and Pacific region | |||||||||
| Malaysia | 92.6 | 74.1 | 68.1 | 85.2 | 31.9 | 75 | 72.2 | ●●● | 59.6 |
| NZGG | 87 | 66.7 | 77.8 | 88.9 | 56.9 | 88.9 | 77.8 | ●●★ | 49.6 |
| CA- BRCA | 81.5 | 68.5 | 54.9 | 77.8 | 47.2 | 88.9 | 77.8 | ●●★ | 47.9 |
| CA-NBOCC | 81.5 | 38.9 | 54.9 | 75.9 | 31.9 | 8.3 | 55.6 | ★★★ | 21.4 |
| JBCS | 57.4 | 24.1 | 27.1 | 55.6 | 4.2 | 30.6 | 38.9 | ★★▲ | 9.4 |
| Consensus statements | |||||||||
| Biedenkopf | 74.1 | 35.2 | 31.3 | 75.9 | 19.4 | 63.7 | 44.4 | ★★★ | 22.6 |
| St. Gallen | 66.7 | 31.5 | 27.8 | 70.4 | 18.1 | 66.7 | 38.9 | ★★★ | 19.8 |
| ESO | 74.1 | 27.8 | 31.3 | 83.2 | 12.5 | 50 | 33.3 | ★★★ | 18.2 |
| D.A.C.H. | 77.8 | 25.9 | 36.1 | 57.4 | 8.3 | 41.7 | 44.4 | ★★▲ | 15.1 |
●, recommend; ★, recommend with modification; ▲, not recommended.
AGO, German Group for Gynecological Oncology; ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network; JBCS, Japanese Breast Cancer Society; ASCO, American Society of Clinical Oncology; NCIE, National Institute for Health and Care Excellence; CCO, Cancer Care Ontario; SIGN, Scottish Intercollegiate Guidelines Network; ACR, American College of Radiology; KCE, Belgium Health Care Knowledge Center; SSO-ASTRO, Society of Surgical Oncology-American Society for Radiation oncology; SEOM, Spanish Society of Medical Oncology; EUSOMA, European Society of Breast Cancer Specialists; CA-NBOCC, Cancer Australia-National Breast and Ovarian Cancer Center; SASK, Saskatchewan Cancer Agency, Malaysia Academy of Medicine of Malaysia; SIOG, Society of Geriatric Oncology; NZGG, New Zealand Guidelines Group; D.A.C.H, German, Australia, Swiss Societies of Senelogy, St Gallen St Gallen Consensus; ESO, European School of Oncology, Biedenkopf the Biedenkopf expert panel members.